AR090425A1 - Precipitacion de las fracciones i-iv-1 para obtener inmunoglobulinas plasmaticas - Google Patents

Precipitacion de las fracciones i-iv-1 para obtener inmunoglobulinas plasmaticas

Info

Publication number
AR090425A1
AR090425A1 ARP130100566A ARP130100566A AR090425A1 AR 090425 A1 AR090425 A1 AR 090425A1 AR P130100566 A ARP130100566 A AR P130100566A AR P130100566 A ARP130100566 A AR P130100566A AR 090425 A1 AR090425 A1 AR 090425A1
Authority
AR
Argentina
Prior art keywords
immunoglobulins
suspension
plasma
cohn
cluster
Prior art date
Application number
ARP130100566A
Other languages
English (en)
Spanish (es)
Inventor
Peter Schwarz Hans
Bruckschwaiger Leopold
Gundinger Thomas
Nrnberger Julia
Teschner Wolfgang
Original Assignee
Baxter Int
Baxter Healthcare Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47833446&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR090425(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Baxter Int, Baxter Healthcare Sa filed Critical Baxter Int
Publication of AR090425A1 publication Critical patent/AR090425A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/16—Blood plasma; Blood serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/30—Extraction; Separation; Purification by precipitation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/145—Extraction; Separation; Purification by extraction or solubilisation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Developmental Biology & Embryology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
ARP130100566A 2012-02-23 2013-02-25 Precipitacion de las fracciones i-iv-1 para obtener inmunoglobulinas plasmaticas AR090425A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261602488P 2012-02-23 2012-02-23

Publications (1)

Publication Number Publication Date
AR090425A1 true AR090425A1 (es) 2014-11-12

Family

ID=47833446

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP130100566A AR090425A1 (es) 2012-02-23 2013-02-25 Precipitacion de las fracciones i-iv-1 para obtener inmunoglobulinas plasmaticas

Country Status (25)

Country Link
US (1) US9782477B2 (https=)
EP (2) EP2817334B1 (https=)
JP (1) JP6291423B2 (https=)
KR (1) KR101930582B1 (https=)
CN (1) CN104245730B (https=)
AR (1) AR090425A1 (https=)
AU (1) AU2013203112B2 (https=)
BR (1) BR112014020602B1 (https=)
CA (1) CA2864715A1 (https=)
CL (1) CL2014002225A1 (https=)
CO (1) CO7081143A2 (https=)
DK (1) DK2817334T3 (https=)
EA (1) EA032478B1 (https=)
ES (1) ES2928954T3 (https=)
HU (1) HUE060195T2 (https=)
IL (1) IL234103B (https=)
MX (2) MX365236B (https=)
MY (1) MY167235A (https=)
NZ (1) NZ628529A (https=)
PL (1) PL2817334T3 (https=)
PT (1) PT2817334T (https=)
SG (1) SG11201405149UA (https=)
SI (1) SI2817334T1 (https=)
TW (1) TWI629283B (https=)
WO (1) WO2013126904A1 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013203043B2 (en) * 2013-03-15 2016-10-06 Takeda Pharmaceutical Company Limited Methods to produce a human plasma-derived igg preparation enriched in brain disease-related natural iggs
CN104004090A (zh) * 2014-06-12 2014-08-27 新疆德源生物工程有限公司 一种人免疫球蛋白的制备方法
CN104004091B (zh) * 2014-06-12 2016-08-17 新疆德源生物工程有限公司 一种人免疫球蛋白的制备工艺
GB201413227D0 (en) * 2014-07-25 2014-09-10 Bioproducts Lab Ltd Process
WO2017025965A1 (en) * 2015-08-13 2017-02-16 Kamada Ltd. Compositions derived from cohn fraction paste and use thereof
US11040068B2 (en) * 2017-04-26 2021-06-22 Alkahest, Inc. Dosing regimen for treatment of cognitive and motor impairments with blood plasma and blood plasma products
ES2991988T3 (es) 2017-10-30 2024-12-05 Takeda Pharmaceuticals Co Detergentes compatibles con el medio ambiente para la inactivación de virus con envoltura lipídica
WO2019219890A1 (en) * 2018-05-17 2019-11-21 Csl Behring Ag Method and system of protein extraction
EP4061826A1 (en) 2019-11-20 2022-09-28 CSL Behring AG Method for extracting a protein from a precipitate and method for precipitating impurities
US11732004B2 (en) * 2020-04-10 2023-08-22 Plasma Technologies, Llc Compositions and methods for simplified high efficiency isolation of proteins
JP2025512143A (ja) * 2020-11-09 2025-04-17 武田薬品工業株式会社 酸化ケイ素吸着を使用する血漿からのｆｖｉｉｉの精製
CN112250757A (zh) * 2020-11-13 2021-01-22 广东深蓝生物科技有限公司 一种猪血浆中蛋白质的提取纯化方法
US11884702B2 (en) * 2020-12-28 2024-01-30 Plasma Technologies, Llc Systems and methods for process scale isolation of immunoglobulin G
CN118580342B (zh) * 2024-05-20 2025-02-07 广东丹霞生物制药有限公司 一种静脉注射用人免疫球蛋白制剂的制备工艺

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE348942B (https=) 1970-06-02 1972-09-18 Statens Bakteriologiska Labor
US3998946A (en) 1975-04-23 1976-12-21 The Regents Of The University Of Minnesota Fibrinogen-free plasminogen-plasmin-free plasma and method of preparing and using same
US4136094A (en) 1977-08-31 1979-01-23 The Regents Of The University Of Minnesota Preparation of intravenous human and animal gamma globulins and isolation of albumin
US4499073A (en) 1981-08-24 1985-02-12 Cutter Laboratories, Inc. Intravenously injectable immune serum globulin
JPS5855432A (ja) * 1981-09-29 1983-04-01 Fujirebio Inc 静脈注射用免疫グロブリンの製法
DK166763C (da) 1983-03-16 1993-07-12 Immuno Ag Immunoglobulin-g-holdig fraktion
US5177194A (en) 1990-02-01 1993-01-05 Baxter International, Inc. Process for purifying immune serum globulins
FR2706466B1 (fr) 1993-06-14 1995-08-25 Aetsrn Concentré d'immunoglobulines G à usage thérapeutique et procédé de production dudit concentré.
US6284874B1 (en) 1994-06-17 2001-09-04 Alpha Therapeutic Corporation Process for separating α1-proteinase inhibitor from cohn fraction IV1 and IV4 paste
US5616693A (en) 1996-07-01 1997-04-01 Alpha Therapeutic Corporation Process for seperating alpha-1-proteinase inhibitor from COHN IV1 +1V4 paste
TW491855B (en) 1996-08-07 2002-06-21 Csl Ltd Purification of immunoglobulins
TW541179B (en) 1997-03-19 2003-07-11 Green Cross Corp Process for preparing immunoglobulin preparation
GB9705810D0 (en) * 1997-03-20 1997-05-07 Common Services Agency Intravenous immune globulin
US5886154A (en) 1997-06-20 1999-03-23 Lebing; Wytold R. Chromatographic method for high yield purification and viral inactivation of antibodies
CN1149100C (zh) 1997-10-23 2004-05-12 三菱制药株式会社 可室温贮存的免疫球蛋白静脉注射制剂
SE0001128D0 (sv) 2000-03-30 2000-03-30 Amersham Pharm Biotech Ab A method of producing IgG
FR2824568B1 (fr) 2001-05-11 2004-04-09 Lab Francais Du Fractionnement Procede de preparation de concentres d'immunoglobulines humaines a usage therapeutique
US7038775B2 (en) * 2001-07-05 2006-05-02 Hamamatsu Photonics K.K. Spectroscopic device
US6893639B2 (en) * 2001-10-19 2005-05-17 Hemacare Corporation Method for high yield purification of immune globulins from blood plasma and blood plasma intermediates
PT1664123E (pt) 2003-09-22 2008-07-16 Kamada Ltd Preparação em larga escala de um inibidor da alfa-1 proteinase e sua utilização
US20070244305A1 (en) 2004-01-30 2007-10-18 Suomen Punainen Risti Veripalvelu Process for The Manufacture of Virus Safe Immunoglobulin
CA2557229C (en) 2004-02-27 2012-07-10 Octapharma Ag A method of providing a purified, virus safe antibody preparation
US7807435B2 (en) 2005-08-11 2010-10-05 Baxter International Inc. Method for the purification of alpha-1 proteinase inhibitor (a1PI)
WO2008113589A1 (en) 2007-03-20 2008-09-25 Csl Behring Gmbh Methods for industrial scale production of therapeutic complement factor h preparations from human plasma
TWI445714B (zh) * 2009-05-27 2014-07-21 Baxter Int 產製用於皮下使用之高濃度免疫球蛋白製備物之方法
AT516600B1 (de) * 2009-07-23 2016-07-15 Baxter Int Herstellung von faktor h (fh) und fh-derivaten aus plasma
WO2011150284A2 (en) * 2010-05-26 2011-12-01 Baxter International Inc. Removal of serine proteases by treatment with finely divided silicon dioxide
AU2010202125B1 (en) * 2010-05-26 2010-09-02 Takeda Pharmaceutical Company Limited A method to produce an immunoglobulin preparation with improved yield
ES2717177T3 (es) 2010-07-23 2019-06-19 Baxalta GmbH Fabricación de proteínas inhibidoras inter-alfa (IaIp) a partir de plasma

Also Published As

Publication number Publication date
HK1205520A1 (en) 2015-12-18
US20130224183A1 (en) 2013-08-29
IL234103B (en) 2019-11-28
CO7081143A2 (es) 2014-10-10
MX365236B (es) 2019-05-28
BR112014020602B1 (pt) 2022-12-20
MX2014010076A (es) 2014-09-22
SG11201405149UA (en) 2014-09-26
ES2928954T3 (es) 2022-11-23
KR20140135996A (ko) 2014-11-27
PL2817334T3 (pl) 2022-11-21
JP2015509506A (ja) 2015-03-30
NZ628529A (en) 2016-09-30
SI2817334T1 (sl) 2022-11-30
CN104245730A (zh) 2014-12-24
DK2817334T3 (da) 2022-10-03
EP4119574A1 (en) 2023-01-18
BR112014020602A2 (pt) 2018-09-11
AU2013203112A1 (en) 2013-09-12
PT2817334T (pt) 2022-10-17
AU2013203112B2 (en) 2016-03-10
KR101930582B1 (ko) 2018-12-18
CA2864715A1 (en) 2013-08-29
EP2817334B1 (en) 2022-09-21
IL234103A0 (en) 2014-09-30
WO2013126904A1 (en) 2013-08-29
EP2817334A1 (en) 2014-12-31
CN104245730B (zh) 2017-09-01
JP6291423B2 (ja) 2018-03-14
MY167235A (en) 2018-08-14
EA032478B1 (ru) 2019-06-28
MX2019005999A (es) 2019-08-21
TWI629283B (zh) 2018-07-11
CL2014002225A1 (es) 2015-01-16
HUE060195T2 (hu) 2023-02-28
TW201348248A (zh) 2013-12-01
US9782477B2 (en) 2017-10-10
EA201491564A1 (ru) 2015-04-30

Similar Documents

Publication Publication Date Title
AR090425A1 (es) Precipitacion de las fracciones i-iv-1 para obtener inmunoglobulinas plasmaticas
AR133787A2 (es) Métodos y composiciones que comprenden polipéptidos recombinantes purificados
BR112015013525A2 (pt) método para produção de uma proteína de fusão, bem como composição compreendendo uma proteína de fusão
AR076800A1 (es) Metodo para producir una preparacion de inmunoglobulina con un alto rendimiento
MX2018009989A (es) Composiciones funcionales derivadas de frijol mungo.
CO5601037A2 (es) Anticuerpos anti-a beta y sus usos
CY1122476T1 (el) Βελτιστοποιημενα μονοκλωνικα αντισωματα εναντι του αναστολεα της οδου του ιστικου παραγοντα (τfρι)
SG10201909806SA (en) Production of t cell retargeting hetero-dimeric immunoglobulins
AR103161A1 (es) Anticuerpos antimiostatina y regiones fc variantes así como métodos de uso
AR106232A1 (es) Anticuerpos anti-pd1 (proteína muerte programada 1) y métodos de uso
MX2019002252A (es) Metodo para producir una proteina de fusion de anticuerpo.
MX2018012749A (es) Etanercept plegado correctamente con alta pureza y un rendimiento excelente.
BR112015031094A2 (pt) células progenitoras renais
BR112012017124C1 (pt) Método para produzir e para purificar um multímero polipeptídico
CO6680653A2 (es) Fabricación del inhibidor inter-alfa(iaip) a partir de plasma
EA201291061A1 (ru) Способ получения изотопа
BR112015018203A2 (pt) Anti-corpos biespecíficos anti-tnf-anti-il-17
CL2015001849A1 (es) Anticuerpos anti-lamp1 y conjugados anticuerpos fármaco, y usos de estos
BR112015022529A2 (pt) meios de cultura de células e processos de produção de anticorpo
BR112016014824A2 (pt) Método para purificar anticorpo que tem ponto isoelétrico baixo
Béguin et al. Integrated proteomic analysis of tumor necrosis factor α and interleukin 1β-induced endothelial inflammation
BR112018008080A2 (pt) método para a fabricação de extratos especiais de symphytum
BR112016018826A8 (pt) anticorpo purificado, ou fragmento de ligação de antígeno, método para a identificação de uma população de células de esperma de mamífero portadoras de cromossomo x, e método in vitro para distorcer uma proporção entre os sexos
MX380226B (es) Proceso para preparar apolipoproteina a-i (apo a-i).
BR112022021450A2 (pt) O cd19 ou fragmento de ligação, método de tratamento de um câncer, composição farmacêutica, ácido nucleico, vetor, e, célula isolada

Legal Events

Date Code Title Description
FC Refusal